第一类的典型示例是微乳头状癌,通常表现出所谓的 HER2 表达的 U 形模式,以细胞膜的基底外侧内衬为特征(图 2)。表达强度可能不同,通常为中度至强度;然而,由于沿细胞膜缺乏完整性,这种基底外侧模式甚至不符合评分 2+的标准。但是考虑到这些癌种中,大约 30%的...
此外,在HER2阴性与阳性的分类上还有一个“灰地带”(equivocal)的定义:当HER2基因的拷贝数介于正常倍数和阳性倍数之间,或者表达量为2+时,结果不能确定其是阴性还是阳性,需要进一步进行FISH或ISH检测。 总之,HER2阴性和阳性的差异常常决定了乳腺癌患者的治疗方案。因此,准确判断HER2的状态对乳腺癌患者的治疗和预后具有重...
第一类的典型示例是微乳头状癌,通常表现出所谓的HER2表达的U形模式,以细胞膜的基底外侧内衬为特征(图2)。表达强度可能不同,通常为中度至强度;然而,由于沿细胞膜缺乏完整性,这种基底外侧模式甚至不符合评分2+的标准。但是考虑到这些癌种中,大约30%的病例携带HER2扩增,因此仍将其视为2+,并需要进行ISH检测。 图2....
Most tumors were grade 2 (64.3%). As per the FISH report, at the time of diagnosis, 27 cases (11.2%) were HER2 FISH positive. All HER2 FISH equivocal cases and one FISH positive case assessed using the 2013 ASCO/CAP HER2 criteria were reclassified to HER2 FISH negative when the 2018 ...
RESULTS: Immunohistochemical examination revealed that among the 338 breast cancer cases, there were 9 (2.7%) HER2-negative cases, 309 (91.4%) HER2-equivocal cases, and 20 (5.9%) HER2-positive cases. The FISH analysis sh...
HER2-targeted therapies for patients with HER2+ breast cancer are rapidly evolving, offering a range of more complex and personalized treatment options. Currently, an array of anti-HER2 monoclonal antibodies, tyrosine kinase inhibitors and antibody–drug
15.Hoda RS, Brogi E, Xu J, Ventura K, Ross DS, Dang C, et al. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 guideline updates on HER2 assessment in breast cancer with equivocal HER2 immunohistochemistry results with focus on cases with HER2/...
RESULTS: Immunohistochemical examination revealed that among the 338 breast cancer cases, there were 9 (2.7%) HER2-negative cases, 309 (91.4%) HER2-equivocal cases, and 20 (5.9%) HER2-positive cases. The FISH analysis showed that there were 226 (66.9%) HER2-negative cases, 13 (3.8%) HER2...
et al. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am. J. Clin. Pathol. 124, 273–281 (2005). Article PubMed Google Scholar Filho, O. M. et al. Impact of HER2 heterogeneity on treatment response of early...
METHODS: One thousand seven hundred and eighty invasive breast cancer cases with equivocal 2+ immunostaining detected by FISH were retrospectively selected from 2010 to 2014, and the HER2/CEP17 dual-probe results were evaluated according to both the 2007 and 2013 ASCO/CAP guidelines for comparative...